L-Arginine

L-Arginine is a conditionally essential amino acid and the substrate for nitric oxide synthase (NOS). Oral supplementation modestly raises plasma arginine, but ~40% first-pass arginase extraction in gut and liver means plasma arginine rises are smaller and shorter than equimolar L-citrulline (which bypasses arginase). This pharmacokinetic disadvantage is the central fact of the monograph: for most cardiovascular and exercise goals, L-citrulline is the pharmacologically superior choice.

Arginine's genuine evidence base is narrower than its reputation. Best-supported indications are (1) mild-to-moderate erectile dysfunction in combination with Pycnogenol (multiple positive RCTs, EAU weak recommendation), (2) preeclampsia prevention in high-risk pregnancies (Makama 2025 meta-analysis, RR 0.52), (3) sickle-cell disease vaso-occlusive pain (Morris 2025 Phase 2 positive), and (4) adjunctive nutrition in pressure ulcers / chronic wounds (as arginine+glutamine+HMB formulas).

The supplement's reputation as a "NO booster" for healthy adults, GH releaser, or pre-workout pump agent is largely unsupported — decades of RCTs show null or weak effects outside the above niches. More concerning: the VINTAGE-MI trial (JAMA 2006) halted early when 6/70 post-MI patients died on arginine versus 0/70 on placebo. Oral arginine is contraindicated after acute myocardial infarction, and caution applies to older adults with established atherosclerosis or endothelial dysfunction. If you are a healthy adult looking to support NO signaling, use citrulline. If you have mild ED and want to try a supplement, consider the arginine+Pycnogenol stack. If you have anything else cardiovascular in your history, discuss with your cardiologist first.

Reading this table: Stars = evidence volume. Type = causal relationship strength. BH = Bradford Hill criteria met (/9). Safety = FAERS / trial signals for THIS specific indication.

Hard rule: Star rating cannot exceed the causal taxonomy ceiling for its Type.

Type codes: DC=Direct causation | PC=Probable causation | UCC=Unreplicated causal | BC=Biomarker correlation | SE=Surrogate endpoint | ME=Mechanistic extrapolation | AHE=Animal→human | OA=Observational | RC=Reverse causation | CF=Confounded | FA=Folk/anecdotal | NE=No evidence BH: 7-9=strong causal | 5-6=moderate | 3-4=weak | 1-2=speculative | 0=none Safety flags: -- No signals | MON Monitor (manageable AEs) | WARN FAERS / trial safety signal | AVOID Contraindicated for this indication

Star rating legend: 5/5 = multiple large RCTs + meta-analyses | 4/5 = several human RCTs | 3/5 = some human pilot | 2/5 = animal or very limited human | 1/5 = none / debunked / harmful

Dosing Table

Formulation Table

Pharmacokinetic note: oral arginine peaks plasma at 1-2 h, half-life ~1-2 h. Sustained elevation requires divided doses. Equimolar oral L-citrulline produces a higher and longer-lasting plasma arginine rise than L-arginine itself.

Erectile Dysfunction (mild-to-moderate) Protocol

Evidence: 4/5 | Key PMIDs: 30770070 (Rhim meta-analysis), 37908749 (Tian combo MA), 12851125 (Stanislavov original), 39279185 (Barbonetti network MA)

Phase 1: Initiation (Weeks 1-2)

• Dose: 2.5 g L-arginine BID (5 g/day total) with 40-60 mg Pycnogenol once daily.
• Monitor: subjective erection quality (IIEF-5 self-scoring at baseline + week 4 + week 8); BP weekly if hypertensive.
• Goal: confirm GI tolerance; identify PDE5i-stacking opportunities.

Phase 2: Therapeutic (Weeks 3-12)

• Dose: maintain 5 g/day arginine + 80-120 mg Pycnogenol.
• Monitor: IIEF-5 at 4-week intervals; cold-sore breakout if HSV-prone.
• Expected outcome: IIEF-5 improvement typically visible by week 4-8. Response rate ~60-70% in clinical literature (Stanislavov 80-90% in original trial — likely overstated).

Phase 3: Maintenance (Week 12+)

• Continue effective dose. If no improvement after 12 weeks, discontinue — unresponsive phenotype (may reflect venous leak or other non-NO etiology).
• Consider adding / switching to PDE5i if insufficient (well-studied additive effect per Xu 2021, PMID 33587304).

Drug Interaction Timing: If adding sildenafil 25-50 mg PRN, take ≥4 h after morning arginine dose to avoid compound hypotension. Monitor BP if using any antihypertensive. Expected Outcomes: IIEF-5 gain of 3-5 points typical in responders; no change in testosterone. Stop/Reassess Criteria: No subjective improvement after 12 weeks; any syncope or symptomatic hypotension; new cardiac symptoms (contraindication check).

Preeclampsia Prevention (OB-directed, high-risk pregnancies) Protocol

Evidence: 4/5 | Key PMIDs: 39800868 (Makama 2025 BJOG, n=2028), 22957482 (Zhu 2013), 37258415, 37789125 (CHERRY, citrulline), 39638148

This protocol is for OB/MFM-directed use only. DO NOT self-initiate arginine in pregnancy. Listed here because the evidence base is strong enough to reference during clinical discussions.

Phase 1: Initiation (early 2nd trimester, high-risk identification)

• Typical trial doses: 3 g/day to 15 g/day (often as arginine + citrulline combination or as arginine-enriched medical food such as Medox or Vitergin used in European trials).
• Monitor: BP weekly; urine protein; fetal growth surveillance per high-risk OB protocol.

Phase 2: Therapeutic (through 3rd trimester)

• Dose: continue trial-dose arginine; adjust per OB guidance.
• Expected biomarker changes: SBP -5.6 mmHg average; reduced sFlt-1/PlGF ratio (in L-citrulline CHERRY trial); reduced FGR rates (RR 0.46).

Phase 3: Postpartum

• Discontinue after delivery unless continuing for lactation support (no data).

Stop/Reassess Criteria: Any sign of maternal hypotension; fetal monitoring concerns; uncertain benefit weighed against any new GI or hemodynamic concern.

Sickle-Cell Disease VOC (hematology-directed) Protocol

Evidence: 4/5 | Key PMIDs: 40270092 (Morris Phase 2 2025), 35426778 (Onalo 2022 pediatric), 41534622 (Foncha 2026 MA)

Inpatient VOC pain management (acute): 100 mg/kg IV loading then IV maintenance per hematology protocol. Outpatient maintenance (under study): oral L-arginine under hematologist supervision; dose and duration per STArT Phase 3 trial protocol (PMID 37587492).

Expected Outcomes: Reduction in opioid requirement during VOC; improved vascular hemodynamics (Onalo 2022). Stop/Reassess Criteria: No data supporting use outside active VOC or specific research protocols.

Interactions Table

Contraindications

• Post-acute myocardial infarction — VINTAGE-MI excess mortality signal (6/70 vs 0/70, trial halted early). Oral arginine is contraindicated after STEMI, at minimum for the 6-month post-event window and likely longer in older adults with endothelial dysfunction.
• Sepsis / critical illness (theoretical) — NO overproduction may worsen hemodynamic instability; enteral nutrition protocols sometimes still use arg+glu+HMB, but this is different from solo supplementation.
• Active herpes simplex (cold sore, genital) — high-dose arginine may promote viral replication; folk wisdom + in vitro mechanism; defer until lesion resolves.
• Known ASS1-deficient malignancy — theoretical: ADI-PEG20 (pegargiminase, JAMA Oncol 2024 PMID 38358753) is therapeutic in mesothelioma and some HCC by depleting arginine; supplementing in these tumors is the opposite of therapy. Low-probability but real concern for older patients with unknown tumor status. (Note: this concern is hypothetical for supplement users; do not use it to fearmonger against arginine in general.)
• Severe renal impairment (GFR <30) — paucity of safety data; aging kidney literature (Frontiers Pharmacol 2020) raises concern over chronic high-dose use; discuss with nephrologist.
• Pediatrics (except under specialist care for SCD or urea cycle disorders) — no routine indication.

Adverse Effects (ranked by frequency in oral supplement use)

1. Diarrhea / GI distress / nausea / bloating — dose-dependent, usually >6 g single dose or >9 g/day total; most common reason for discontinuation.
2. Headache — likely vasodilation-related; mild and transient.
3. Flushing / lightheadedness — vasodilation; more pronounced in BP-sensitive individuals.
4. Cold-sore / HSV reactivation — community-reported; plausible mechanism (lysine/arginine ratio).
5. Hypotension — especially when stacked with PDE5i or antihypertensives.
6. Fatigue / asthenia — reported in FAERS suspect-only subset (~62 reports); unclear causality.

FAERS Signal Table (from BioMCP, OpenFDA 2026-04-17)

Reading FAERS data: Supplement FAERS data is noisy — most "serious" reports for arginine are from IV parenteral nutrition formulations (CLINIMIX, TROPHAMINE, AMINOSYN, KABIVEN) or perindopril-arginine (ACE inhibitor salt), NOT oral supplementation. Reports of cerebral hemorrhage, AKI, sepsis, hypotension reflect the ICU parenteral-nutrition population. Apply the FAERS-supplement-noise filter. The oral-attributable suspect signal is ~370 reactions total, dominated by GI + fatigue + headache — mechanistically consistent with vasodilation. The dyspnea cluster in the hypertension-indication subset is the most concerning quasi-signal and aligns with the VINTAGE-MI pathophysiologic lesson.

Monitoring Table

Special Populations

Renal Impairment

Hepatic Impairment

Post-Myocardial Infarction

Antagonism / caution:

• High-dose Lysine (>3 g/d) may compete with arginine for absorption; matters for HSV-prone users who WANT to suppress arginine's viral-substrate effect.
• Avoid stacking with nitrates (nitroglycerin, isosorbide) — severe hypotension.

Sex-Specific Considerations

Genetic Modifiers

No clinically significant MTHFR / APOE / COMT effect documented for L-arginine specifically.

Disclaimer: This section captures real-world user reports from online communities. None of this constitutes clinical evidence. N-sizes are approximate. Selection bias, placebo effect, and recall bias are inherent. Presented for completeness, not as medical guidance.

Dominant Sentiment

Mixed-to-negative across ~1000-2000 aggregated community mentions (Reddit, Longecity, bodybuilding forums, WebMD reviews). The near-universal biohacker consensus in 2024-2026 is "citrulline > arginine" for cardiovascular and exercise goals. Arginine retains a defensible niche in the arginine + Pycnogenol ED stack and as a cheap legacy option. Older bodybuilding forums universally call NO-boosters "the biggest scam in supplement history."

What Users Report

Community Dosing vs Clinical

Popular Stacks (Community)

Red Flags & Skepticism Notes

• MLM involvement: Some network-marketing brands push high-dose arginine (Synergy ProArgi-9, Juice Plus-adjacent) with "Nobel Prize heart health" messaging referencing Ignarro 1998 NO Nobel. Flag these hard; such products are typically 2-5x the price of equivalent USP arginine.
• Influencer concentration: Hype peaked 2005-2015 (BSN NO-Xplode era). Current biohacker influencers (Attia, Rogan) rarely recommend arginine; Pycnogenol+arginine ED stack is the one exception still promoted by sexual-health voices.
• Proprietary blends: Pre-workouts routinely hide sub-therapeutic arginine doses in proprietary blends (44% of ingredients hidden per multi-ingredient review). Avoid; buy single-ingredient USP arginine if trialing.
• Commercial bias: Most positive reviews on men's-health sites are affiliate-driven. Peer forums (Reddit, Longecity) are more honest.
• Astroturfing signals: AAKG and "NO booster" categories show unusually high review volume on generic-looking marketplace listings; suspect paid reviews.

Folk vs Clinical Reality Check

Community consensus is more skeptical than the clinical literature for solo arginine (CV, pump, GH) and more enthusiastic for the arginine+Pycnogenol ED combo. Biohackers correctly intuit that citrulline is pharmacologically superior for sustained NO — this aligns with the first-pass arginase / bioavailability literature. Divergences are mostly explained by placebo-washout at community dosing (3-6 g) versus therapeutic clinical dosing (≥9 g for BP), and by responder-heterogeneity from unmeasured ADMA/ARG1 status. The HSV-trigger folk wisdom has a plausible in-vitro mechanism but weak direct RCT evidence — a classic "probably real in HSV-prone individuals, invisible in mixed populations" signal.

Mechanisms with clinical translation

• NO substrate via eNOS: L-arginine → citrulline + NO. Underlies vasodilation, BP reduction, and endothelial effects. Clinically translated for BP (meta-analyses) and ED. Caveat: plasma arginine rarely limits NO production in healthy endothelium (Km of eNOS for arginine ~3 μM; plasma arginine ~80-100 μM). The "arginine paradox" — why supplementation helps despite normal substrate availability — is explained by eNOS uncoupling, ADMA inhibition, and intracellular compartmentalization.
• eNOS uncoupling in disease: Under oxidative stress or BH4 deficiency, eNOS produces superoxide instead of NO. In this state, arginine supplementation may actually increase superoxide output (VINTAGE-MI mechanism hypothesis).
• Arginase compartmentalization: Red-cell ARG1 is the dominant human sink for arginine (not endothelial arginase as in rodent models). PMID 40729962 Heuser 2025.
• ADMA axis: Asymmetric dimethylarginine is a competitive endogenous inhibitor of eNOS. High-ADMA states (CKD, OSA, CVD) blunt arginine response. PMIDs 40797410, 40429627.
• Urea cycle / ammonia clearance: Clinically essential in CTLN1 (citrullinemia); therapeutic rescue dose.
• Immune / wound healing: Substrate for ornithine → proline → collagen; also iNOS → NO for macrophage function.
• GH secretion: IV arginine 0.5 g/kg reliably stimulates GH (standard pituitary provocation test). Oral doses in supplement range produce minimal, blunted, age-attenuated response.

Mechanisms with weak/no clinical translation

• Mitochondrial biogenesis via NO-cGMP-PGC1α (PMID 39707340, preclinical in diabetic cardiomyopathy) — promising but not yet clinically actionable.
• LAT1-NRF2 axis in placenta (PMID 41087351) — mechanistic explanation for preeclampsia effect, not independently actionable.
• iNOS reclassification (PMID 40389042) — may matter for inflammatory contexts; not yet actionable.

Clinical Trials (from BioMCP / ClinicalTrials.gov)

330 total registered trials for "arginine" on ClinicalTrials.gov; many are vasopressin/oxytocin/pegargiminase trials captured by keyword match rather than oral L-arginine supplementation studies. Above are representative oral-arginine supplementation trials.

Regulatory Status

• FDA: L-arginine HCl injection approved as R-Gene 10 (NDA016931, Pfizer/Pharmacia) — IV provocative test for pituitary GH reserve. Oral L-arginine is marketed as dietary supplement under DSHEA — no FDA drug approval required. No FDA black-box warning despite VINTAGE-MI signal.
• EMA: LysaKare (L-arginine + L-lysine HCl, EMEA/H/C/004541) authorized for renal protection during Lutathera PRRT (radioligand therapy). Multiple amino-acid parenteral nutrition formulations authorized.
• WADA 2026: NOT prohibited. L-arginine is a natural amino acid; only GH-releasing peptides (GHRP, CJC-1295) are prohibited under S2. Use informed-sport-certified product to avoid contamination.
• Regulatory context: Never developed as a CV drug after VINTAGE-MI derailed the post-MI indication. Commercial viability and lack of patent incentive keep it in supplement channels.

Evidence Classification (Mode 5)

Quality Concerns

• Appeal to nature: "It's just an amino acid, can't be harmful." VINTAGE-MI refutes this directly for post-MI context.
• Appeal to authority: "Nobel Prize for NO" (Ignarro 1998) is misapplied — Nobel was for eNOS discovery, not for arginine supplementation efficacy. MLM marketing exploits this conflation.
• Hasty generalization: Extrapolating IV arginine GH-provocation response to oral supplementation for GH boosting. Dose, route, and context are radically different.
• Cherry-picking: ED meta-analyses include Pycnogenol-combo trials mixed with solo trials; pulling apart shows solo arginine effect is weaker than combo.
• Argument from popularity (bodybuilding): NO-booster category was a multi-billion-dollar segment based on pump-feel rather than ergogenic data. Community has since corrected this.
• Sunk cost / legacy: Arginine retains RCT volume advantage over citrulline simply because it was studied first; does not mean it is the better choice.

Evidence Gaps

• No head-to-head RCT comparing arginine vs citrulline at equimolar doses for BP, ED, or preeclampsia.
• No genotype-stratified RCT (NOS3, ASS1, ARG1) identifying who responds to arginine.
• No large Phase 3 outcomes trial for preeclampsia prevention (Makama 2025 calls for this explicitly).
• No long-term (>12 months) safety data in chronic high-dose (>9 g/d) use beyond post-MI signal.
• Sparse 2024-2026 data on oral arginine for male fertility / sperm quality — citrulline has gotten the attention.
• No clear understanding of tachyphylaxis (community "stops working after 2-3 weeks" anecdote).
• No modern Phase 3 trial explicitly replicating or refuting VINTAGE-MI with contemporary post-MI care.

Bias Flags (Mode 4: First Principles)

• Supplement industry overstates: "NO booster" marketing, proprietary blends, AAKG positioning — inflates perceived efficacy.
• Legacy RCT advantage: Arginine's first-mover position in NO-substrate research creates publication volume that overstates its superiority over citrulline.
• Responder self-selection: Positive anecdotes come from the ~30-60% who respond; the majority null response is under-reported.
• VINTAGE-MI narrative softening: Subsequent reviews sometimes downplay the trial ("small N," "old patients only") — but the mechanistic hypothesis (eNOS uncoupling in aged/damaged endothelium producing superoxide) has only strengthened since 2006.
• Pharma disinterest: Arginine is not patentable; no sponsor with incentive to replicate VINTAGE-MI with modern care or to push for regulatory upgrade of indication.

Marketing Red Flags

• Industry marketing: "NO booster" and "pump" categories (2005-2015 peak); proprietary pre-workout blends hiding sub-therapeutic doses; AAKG as "superior form" despite refutation (Campbell 2006); MLM "Nobel Prize heart health" messaging.
• Influencer economics: Peer biohacker community (Attia, Rogan, Huberman) largely doesn't push arginine in 2024-2026 — a mild countersignal to legacy marketing. Men's-health affiliate sites still promote arginine+Pycnogenol combo products (Prelox, Lady Prelox).
• Counter-narrative manipulation: Pharma has no meaningful incentive to fearmonger arginine (it is not a patented competitor to any product). VINTAGE-MI signal originated from academic investigators, not a competitor — this lends it credibility.
  • Wins if you take it: supplement industry (low-margin staple), Pycnogenol combo product brands (Horphag, Prelox), MLM distributors, research groups sustaining grant pipeline on arginine trials.
  • Wins if you don't: citrulline manufacturers (gaining share), PDE5i pharma (ED market retention), cautious cardiologists (fewer patient adventures post-MI).

Practical Considerations

• Health utility score: 5/10 — real evidence for narrow indications (ED+Pycnogenol, preeclampsia in high-risk pregnancy, SCD VOC, wound healing in clinical nutrition contexts); null-to-weak for exercise/pump/GH; contraindicated post-MI. Compound-intrinsic score; NOT a comment on fit to any stack.
• Opportunity cost: Low financial ($5-15/month for USP arginine); moderate attention (GI limits compliance); displaces citrulline which is usually the better choice for the same goals.
• Verdict: CONDITIONAL
• Conditions:
  • USE if: mild-to-moderate ED and wanting to trial a supplement stack before PDE5i (arginine + Pycnogenol 5 g / 80-120 mg).
  • USE if: OB/MFM has recommended arginine for preeclampsia prevention in a high-risk pregnancy.
  • USE if: sickle-cell disease VOC, under hematologist direction.
  • USE if: chronic wound and a clinical nutritionist recommends arg+glu+HMB.
  • CONSIDER if: mild hypertension and seeking a non-pharmacologic adjunct (but prefer citrulline for pharmacokinetic reasons).
  • AVOID if: any history of MI, acute coronary syndrome, or active atherosclerosis — until cardiology clears.
  • AVOID if: active HSV outbreak.
  • SKIP in favor of citrulline if: general NO support, exercise, pump, or cardiovascular maintenance is the goal.
  • SKIP if: hoping for oral GH boost — it doesn't work at these doses.

Bottom Line

L-arginine is a narrow-utility supplement with a few well-supported niches (ED+Pycnogenol, high-risk preeclampsia, SCD, clinical wound nutrition) and a large legacy-marketing halo that exceeds its evidence base. For most cardiovascular and exercise goals, L-citrulline is pharmacologically superior — better absorbed, longer-acting, gentler on the GI tract, cheaper effective dose. The VINTAGE-MI safety signal is real and specific: do not take arginine after an acute MI. For a healthy adult with no specific indication, arginine is not a compelling supplement choice; for specific narrow indications where evidence exists, it can be useful. Choose deliberately based on indication, not on NO-substrate marketing generalities.

Brands & Product Selection

• USP-grade free-base L-arginine (bulk powder or capsules) from reputable brands (NOW Foods, Bulk Supplements, Pure Encapsulations, Doctor's Best) at $0.05-0.15/g.
• For ED stack: consider Prelox or Lady Prelox (Horphag-formulated arginine + Pycnogenol) — standardized, matches clinical trial formulation. More expensive ($40-60/mo) but consistent dosing.
• For wound healing: Juven, Arginaid Extra, or Abound (standardized arg+glutamine+HMB medical foods) — typically insurance-covered with prescription.
• Avoid: Proprietary blends (pre-workouts with undisclosed arginine content); AAKG-only products (no ergogenic advantage over free base); MLM brands with "Nobel Prize" marketing at 3-5x USP price.
• CoA: Request Certificate of Analysis for heavy metals and microbial contamination if buying bulk powder. Informed-Sport certification for competitive athletes.

Storage & Handling

• Store in cool, dry place (<25°C). Powder is hygroscopic — keep desiccant in container after opening.
• Capsules stable 2-3 years at room temperature; powder ~1-2 years once opened.
• Liquid formulations (occasional) have shorter shelf-life and are typically inferior to powder/capsule.
• Rancidity is not a concern (amino acid, not a fat/oil).

Palatability & Compliance

• Free-base arginine has a bitter, slightly fishy taste in water — mix with citrus juice or take capsules.
• Arginine HCl is more soluble but acidic; buffer with a small amount of bicarbonate or take with food.
• Divided dosing (2-3x/day with meals) is essential for GI tolerance at therapeutic ≥5 g/day.
• Biggest compliance killer: GI distress at >6 g single dose. Most people who quit do so from diarrhea, not from lack of effect.

Exercise & Circadian Timing

• Pre-workout use (bodybuilding paradigm): weak evidence; citrulline malate is the better choice for pump/performance.
• Preschedule before sex (ED indication): 45-60 min before intimacy if using for acute erectile support; chronic daily dosing is the evidence-based pattern (not PRN).
• AM vs PM: no strong circadian evidence; divided dosing AM/PM with meals is standard.
• Avoid PM dose if stimulation or insomnia occurs (minority experience; some report opposite).

Reference Ranges (Expected Biomarker Changes)

Cost

• USP arginine powder (bulk): ~$0.05-0.10 / g. At 5 g/day, ~$8-15/month.
• Capsule form (500-1000 mg): ~$0.10-0.20 / g. At 5 g/day, ~$15-30/month.
• Arginine + Pycnogenol combos (Prelox): ~$40-60/month.
• Medical food (Juven/Abound): ~$80-150/month (prescription, often insurance-covered).
• L-Citrulline comparison: ~$0.08-0.20 / g; 3-6 g/day produces superior plasma arginine response; often better value for NO-substrate goals.

• Whether VINTAGE-MI's excess mortality signal extends beyond post-STEMI elderly to broader atherosclerosis populations.
• Whether genotype stratification (NOS3, ARG1, ASS1, DDAH variants) can identify a "super-responder" subset.
• Whether the preeclampsia effect is specifically an arginine effect or a general NO-substrate / citrulline effect.
• Whether chronic high-dose use (>5 years) causes subclinical endothelial senescence (aging-kidney / aging-endothelial preclinical signals).
• Whether oral arginine has any meaningful GH effect in non-elderly, non-obese adults at sub-pharmacologic doses.
• Whether the "tachyphylaxis" community anecdote reflects a real biological phenomenon or placebo-washout.
• Whether topical arginine formulations (hair, skin) have any skin-level effect beyond vehicle.
• Whether arginine is unsafe in occult ASS1-deficient malignancy (theoretical concern never tested).
• Whether lysine co-supplementation materially changes HSV outbreak frequency in HSV-positive supplement users.
• Optimal dose and timing for arginine+Pycnogenol ED stack — original Stanislavov dose has not been formally optimized.

Meta-Analyses & Systematic Reviews

• PMID 22137067 — Dong 2011, Am Heart J. BP meta-analysis: SBP -5.4 mmHg, DBP -2.7 mmHg.
• PMID 34967840 — Shiraseb 2022, Adv Nutr. Dose-response BP meta-analysis: SBP -6.4, greater DBP effect in females.
• PMID 27660594 — McRae 2016, J Chiropr Med. Umbrella review of arginine meta-analyses.
• PMID 19056561 — Bai 2009, Am J Clin Nutr. FMD improvement when baseline FMD low.
• PMID 30577559 — Rodrigues-Krause 2018, Nutrients. Endothelial markers in CV/metabolic disease.
• PMID 30770070 — Rhim 2019, J Sex Med. ED meta-analysis: OR 3.37 IIEF improvement.
• PMID 37908749 — Tian 2023, Front Endocrinol. L-arginine + Pycnogenol ED meta-analysis.
• PMID 33587304 — Xu 2021, Andrologia. L-arginine + PDE5i superior to PDE5i alone.
• PMID 39279185 — Barbonetti 2024, J Sex Med. Network meta-analysis: arginine+Pycnogenol exceeds MCID.
• PMID 39800868 — Makama 2025, BJOG. Preeclampsia meta-analysis: RR 0.52 prevention, RR 0.23 severe PE.
• PMID 22957482 — Zhu 2013, Hypertens Pregnancy. BP reduction in pregnant women.
• PMID 35667267 — Xu 2022, Clin Nutr. Improved neonatal outcomes in HTN/IUGR pregnancies.
• PMID 34965876 — d'Unienville 2021, J Int Soc Sports Nutr. NO precursors and endurance — arginine weak.
• PMID 39796467 — Huang 2024, Nutrients. Swimming supplements network MA.
• PMID 28537329 — Cereda 2017, J Nutr Health Aging. Disease-specific wound nutrition.
• PMID 34444657 — Arribas-López 2021, Nutrients. Arginine + glutamine pressure ulcer.
• PMID 24844870 — Vidal-Casariego 2014, Clin Nutr. Arginine-enriched formulas reduce H&N fistula.
• PMID 28429459 — Bath 2017 Cochrane. NO donors / L-arginine in acute stroke (insufficient).
• PMID 17443623 — Meher 2007 Cochrane. NO for preeclampsia prevention (insufficient 2007).
• PMID 37428872 — Pels 2023 Cochrane. NO interventions for fetal growth restriction.
• PMID 38775255 — Bolarinwa 2024 Cochrane. Antioxidants including arginine for SCD.
• PMID 38345088 — Langer 2024 Cochrane. Nutritional interventions for pressure ulcers.
• PMID 32677037 — Moore 2020 Cochrane. Diabetic foot ulcer nutrition.
• PMID 41534622 — Foncha 2026, Clin Nutr ESPEN. SCD arginine meta-analysis.

Landmark RCTs

• PMID 16391217 — Schulman 2006 VINTAGE-MI, JAMA. Post-MI excess mortality (6/70 vs 0/70, DSMB halt).
• PMID 12851125 — Stanislavov 2003, J Sex Marital Ther. First positive L-Arg + Pycnogenol ED trial.
• PMID 17703218 — Stanislavov 2008 Prelox crossover.
• PMID 21618639 — Aoki 2012, Japanese Pycnogenol + arginine IIEF study.
• PMID 40270092 — Morris 2025, Am J Hematol. Phase 2 positive for SCD VOC pain.
• PMID 35426778 — Onalo 2022 pediatric SCD hemodynamics.
• PMID 37587492 — STArT Phase 3 SCD protocol, 2023.
• PMID 39638148 — Winer 2025, Am J Clin Nutr. Citrulline in established preeclampsia multicenter.
• PMID 37789125 — Ormesher 2024, CHERRY trial citrulline in chronic HTN pregnancy.
• PMID 41248623 — Borges 2026. Arginine RCT: vasodilation yes, muscular performance no.
• PMID 41245968 — Mardokhi 2025. No anaerobic enhancement in female athletes.
• PMID 40316462 — Radovanovic 2025 ILDA COPD study.
• PMID 41364169 — Micker 2025. PAD stratified by lipid disorder.
• PMID 39683461 — Porto 2024. Null post-exercise CV/autonomic recovery.
• PMID 40389021 — Porto 2025. Null nitric oxide post-exercise.
• PMID 39985883 — Sedding 2025 CIPER trial citrulline+BH4 in PAD (Phase 2 positive).
• PMID 38745327 — Torkaman 2024. Arginine improved sexual function in women with MDD.
• PMID 38358753 — Szlosarek 2024 ATOMIC-Meso, JAMA Oncol. Pegargiminase in mesothelioma.

Mechanism & PK Studies

• PMID 40729962 — Heuser 2025, Redox Biol. RBC Arg1 dominant human arginine sink.
• PMID 39707340 — Fiordelisi 2024, Cardiovasc Diabetol. Mitochondrial biogenesis via NO-cGMP-PGC1α.
• PMID 40797410 — ADMA axis in OSA 2025.
• PMID 40429627 — ADMA disrupts tumor antigen presentation, 2025.
• PMID 41087351 — LAT1-NRF2 axis in preeclampsia, Nat Commun 2025.
• PMID 40389042 — iNOS reclassification, Pharmacol Res 2025.
• PMID 38587550 — Global arginine bioavailability in pulmonary hypertension.
• PMID 32140997 — Rashid 2020, Paediatr Drugs. Citrulline bypasses arginase.
• PMID 32568925 — Figueroa 2020, Exerc Sport Sci Rev. Citrulline vascular/muscular adaptations in older adults.
• PMID 36904267 — Park 2023, Nutrients. Citrulline generally outperforms arginine for sustained NO.
• PMID 40944179 — Figueroa 2025, Nutrients. Citrulline microvascular + muscle strength in T2DM.
• PMID 41938116 — 2026 citrulline protects against heat-stress sperm damage.

Disease-Specific

• PMID 40325816 — Vlachakis 2025. Endothelial function biomarkers review.
• PMID 38675437 — Hillsley 2024, Pharmaceuticals. Arginine/citrulline HTN trial design audit.
• PMID 36282078 — Cormio 2011, citrulline for mild ED.
• PMID 38696907 — Santo 2024, arginine-ONS chronic wounds.
• PMID 39454323 — Mehl 2025 cost-effectiveness of arginine-ONS.
• PMID 38364050 — Yang 2024 arginine-nanoenzyme diabetic wound (preclinical).
• PMID 40083304 — Dinges 2025 HFpEF/HFrEF NO metabolites.
• PMID 40795471 — Vázquez-Abuín 2025 sGC stimulation HFpEF rat.
• PMID 32640613 — Ismaeel 2020 NO system in PAD.
• PMID 38819617 — Tausendfreund 2024. Somatotroph axis in aged multimorbid.
• PMID 32236441 — Bologna 2020 arginine test HPA axis.
• PMID 34418530 — Oron 2022 combined arginine + clonidine GH stim test.
• PMID 38644716 — Vaishnavi 2025 pharmacogenomic review arginine in pregnancy.
• PMID 35309121 — Cheng 2022 citrullinemia genetics.
• PMID 35433176 — CTLN1 case report.
• PMID 40837674 — Deng 2025 CTLN1.
• PMID 39765161 — Ogawa 2025, Clin Nutr Japan. HMB + arginine + glutamine preop cardiac surgery.
• PMID 40914430 — Ogawa 2025, J Cardiol. Inflammation secondary analysis same trial.
• PMID 39564822 — Naderipour 2024 preeclampsia in high-risk.
• PMID 37258415 — Menichini 2023 preeclampsia maternal/fetal outcomes.
• PMID 39930022 — Ushida 2025 preeclampsia supplements review.
• PMID 34973154 — Long-term high-dose arginine in vasculogenic ED.

Pre-workout / Exercise Negative

• PMID 36771366 — Gonzalez 2023 NO-precursor review (weak strength evidence).

Regulatory & Safety Context

• R-Gene 10 package insert — FDA-approved IV L-arginine HCl for pituitary provocation.
• LysaKare (EMEA/H/C/004541) — EU authorized for PRRT renal protection.
• Frontiers Pharmacol 2020 — Detrimental chronic arginine on aging kidney (preclinical).
• Aging-US — Endothelial senescence long-term arginine.